American Society of Clinical Oncology Developing First Clinical Trial

By Vicki Brower
At its June 1 annual meeting, the American Society of Clinical Oncology (ASCO) announced its first clinical trial. The trial aims to offer advanced cancer patients off-label access to approved targeted drugs based on genetic driver mutations and to gather information on efficacy and toxicity across cancer types. ASCO stated that it seeks to broaden access to drugs for patients in community settings who have exhausted standard-of-care therapies and to collect "real world" outcomes data in a prospective registry.
The study, called TAPUR (Targeted Agent and Profiling Utilization Registry), will include patients with advanced solid cancers, multiple myeloma, and nonHodgkin lymphoma whose tumors have a genomic variation or mutation known to be a drug target, such as the epidermal growth factor receptor and B-RAF. Five companies are supplying at least 13 drugs, free to participants, which target more than 15 genomic variants. ASCO is writing the protocol for the study and hopes to begin patient enrollment in January 2016. It is not yet releasing figures on cost of the study, or its length, but expects that more information will become public when the protocol is finalized.
Implementing Personalized Medicine
"TAPUR springs from the challenges of implementing personalized medicine in clinical medicine and has been in development since 2013," said Richard Schilsky, M.D., chief medical officer of ASCO. "A major challenge for oncologists who aim to provide personalized medicine to their patients is obtaining drugs predicted to be beneficial based on genomic testing of the tumor but which would be off-label and, as such, only available through a clinical trial or not at all," Schilsky said. Clinical reports suggest that 30%-80% of advanced solid tumors harbor potentially actionable genomic variants, but outcomes of patients treated on the basis of such tests remain largely anecdotal or unknown, he said. That is the reason for the registry.
TAPUR is one of several recent biomarker-driven clinical "basket" trials designed to advance personalized, or precision, medicine and expedite the clinical trial process. They share the principle that cancers should be grouped by and tested for genetic mutations, rather than solely by tissue of origin. Another such trial is the National Cancer Institute's MATCH, a phase II trial now enrolling patients, which will sequence the DNA of 3,000 advanced cancer patients for actionable mutations. Patients will be grouped into cohorts of 20-30 according to mutation, rather than anatomical site of tumor, and treated with approved or investigational targeted drugs. Another recent innovative trial is the Lung Cancer Master Protocol, in which five companies test their targeted drugs in squamous cell lung cancer. For this study, researchers are using one genomic test to screen patients' tumors, and drugs are not compared with each other. Rather, they are compared with the standard of care, according to Roy Herbst, M.D., Ph.D., Ensign Professor of Medicine and chief of medical oncology at Yale University in New Haven, Conn., who is directing the study. An earlier trial, I-SPY2, which began in 2010, tested multiple drugs in newly diagnosed breast cancer patients before surgery who were stratified according to 10 biomarkers. This trial revealed, among other findings, that veliparib, a poly(ADP-ribose) polymerase inhibitor, is effective in triplenegative breast cancer.
"By changing the treatment paradigm to the genotype-to-phenotype approach, we are advancing translational research at a much faster pace than ever, and TAPUR [and other trials] will help to hasten that process even further," said Arturo Loaiza-Bonilla, M.D., assistant professor of clinical medicine in the division of h e m a t o l o g yoncology at the U n ive r s i t y o f Pe n n s y l v a n i a in Philadelphia. "The new treatment paradigm in translational and personalized g enomic oncology is to look first at the genetic makeup of the cancer (genotype), target the driving mutations, and then use the phenotype mostly for classification and less for treatment purposes," he said.
Unlike NCI, ASCO has no established clinical trial mechanisms, "so we've had to build them from the ground up," Schilsky said. NCI has an extensive infrastructure of thousands of designated clinical sites around the country and is opening MATCH at many of these sites. By contrast, TAPUR will open initially at only three sites: the Michigan Cancer Research Consortium, the Cancer Research Consortium of West Michigan, and the Carolinas Healthcare System. Those sites conduct clinical trials for NCI and the pharmaceutical industry.
TAPUR will accept tumor biopsy samples processed through any CLIA (Clinical Laboratory Improvement Amendments)-certified lab, rather than a central lab with uniform assays. ASCO will collaborate and share data with The Netherlands Center for Personalized Cancer Treatment, a Utrecht-based coalition of three Dutch cancer centers, using a protocol similar to what ASCO is developing for TAPUR. news survivor, and patient advocate who consults for TAPUR and was involved in the I-SPY2 study, among other trials.) "It will be less rigorous than other trials but more generalizable," she said. The regulatory pathway to gaining approval for new indications from the TAPUR study will need to be worked out with the U.S. Food and Drug Administration, Perlmutter said.
Broad Patient Inclusiveness
One hallmark of TAPUR is its inclusiveness. It will accept a broader patient population than typical clinical trials, such as patients with a lower performance status than those eligible for MATCH and other trials, who will generally have other trial options available to them. "Patients in TAPUR will have malignancies that have progressed after at least one or two lines of standard chemotherapy, who have already undergone genomic testing by a commercially available platform, and who are running out of options," Loaiza-Bonilla said.
"TAPUR is ideal for a patient that for whom the off-label targeted drug has been difficult due to high copay, ineligibility for clinical trial, or insurance denial," Loaiza-Bonilla said. One major difference between MATCH and TAPUR is that MATCH will have more drugs available to patients, both approved and investigational.
With a decentralized design, TAPUR will enable a patient's own oncologist to send tumor biopsy samples to be sequenced to a local CLIA-certified lab, and the physician will select a drug to test on the basis of the tumor's genomic profile. "An advantage to TAPUR is that we can use the information from several genomics platforms and do not need a fresh biopsy [sample] for eligibility," Loaiza-Bonilla said. If a drug-target match is not made, the oncologist can consult a molecular tumor board, which will review the genomic and clinical aspects of the case and suggest potential therapies either in or off the study, he said. As with any clinical trial, all patients in the TAPUR study will be monitored for efficacy, including tumor response, progression-free survival, overall survival, and side effects.
Although patients will receive the drugs for free, ASCO expects that patients' insurance will cover their care, including routine blood tests, antibiotics, and hospitalizations. ASCO did not, however, describe agreements with insurers. Three committees will oversee TAPUR, each of which will include investigators, genomics experts, and patient representatives. A steering committee will oversee study operations, develop data sharing and publication policies, review plans to add or remove drugs from a study, and approve additional study sites. The molecular tumor board will review proposed drugtarget matches and discuss with physicians possible treatments, on or off study. The data and safety monitoring board will review results independently to analyze and monitor side effects.
Some physicians, such as LoaizaBonilla, will have some patients who participate in TAPUR and others in MATCH. Oncologists will need to decide which trial is best suited for their patients, he said.
"The two studies are completely different and complement each other," he said. "TAPUR will enable patients to get off-label [targeted] therapies for free, which may or may not work, without leaving their [physician's medical] practice," Perlmutter said. TAPUR patients will not need new biopsies, whereas MATCH patients will. MATCH will have more scientific rigor. TAPUR's tumor biopsy samples will be processed by any CLIA-certified lab available to clinicians. For MATCH, however, fresh biopsy samples will be required and processed in the same way, at one of four sites. So the data gleaned from that trial will be "more like comparing apples to apples," Loaiza-Bonilla said. Another difference is that with TAPUR, the patient's physician will choose the treatment, whereas for MATCH the primary investigator for each arm will choose the treatment in consultation with the patient's doctor.
"At the crux, TAPUR will collect data, whereas MATCH is a collection of phase II trials meant to find an endpoint, not just observe what happens," said Barbara Conley, M.D., co-primary investigator of MATCH and associate director of the Cancer Diagnosis Program in the division of cancer treatment and diagnosis at the National Cancer Institute. "If a trial in MATCH meets predesignated endpoints, we have some flexibility, and that trial will be expanded," she said. Alice P. Chen, M.D., acting head of the Early Clinical Trials Development Program in the same NCI division, noted that treatment selection in MATCH is being done in a strictly "rule based," computerized process, in contrast to TAPUR. In MATCH, an opportunity to rebiopsy and resequence samples from patients who relapse will be available, whereas it is unclear whether patients who relapse in TAPUR will be offered new treatments-and on what basis if new biopsies are not done.
"While TAPUR is not the be-all and end-all [of clinical trials], it's a step in the right direction," Perlmutter said. The more opportunities there are to learn from, and the more patients who can get targeted treatments, the better, she said. 
Scientists Journey Into Genomes Via CRISPR-Cas9
By Delthia Ricks Cancer researchers are testing an evolving gene-editing technology that lets them manipulate DNA. Cold Spring Harbor Laboratory (CSHL) in New York is one of dozens of institutions using the technique-clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9-to investigate genomes.
The revolutionary technology has drawn a spotlight in and out of cancer research because of the simplicity, precision, and speed with which researchers can manipulate the basic chemical components of life. But even as this potent form of gene editing has stirred the research community with its promise, the technology is coming under scrutiny. A group of influential scientists convened in California earlier this year to discuss ethical concerns that CRISPRCas9 raised and called for a moratorium on using it in germline research.
Investigators at CSHL, however, along with a growing number of cancer
